What is Leerink Partnrs’ Estimate for HALO FY2025 Earnings?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Research analysts at Leerink Partnrs reduced their FY2025 earnings estimates for shares of Halozyme Therapeutics in a research note issued to investors on Sunday, January 12th. Leerink Partnrs analyst D. Risinger now expects that the biopharmaceutical company will post earnings per share of $4.96 for the year, down from their prior forecast of $5.11. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.86 per share. Leerink Partnrs also issued estimates for Halozyme Therapeutics’ Q4 2025 earnings at $1.57 EPS, FY2026 earnings at $7.05 EPS, FY2027 earnings at $8.77 EPS and FY2028 earnings at $9.16 EPS.

Several other research analysts have also recently issued reports on the company. JMP Securities increased their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Wells Fargo & Company dropped their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday. JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price objective for the company from $52.00 to $57.00 in a report on Thursday, September 19th. HC Wainwright increased their target price on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Finally, Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $60.89.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO opened at $55.37 on Wednesday. The firm’s 50 day simple moving average is $49.75 and its 200-day simple moving average is $54.07. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. Halozyme Therapeutics has a one year low of $33.15 and a one year high of $65.53. The firm has a market cap of $7.04 billion, a PE ratio of 18.33, a price-to-earnings-growth ratio of 0.40 and a beta of 1.24.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HALO. Congress Asset Management Co. increased its holdings in shares of Halozyme Therapeutics by 446.5% during the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after acquiring an additional 1,988,238 shares in the last quarter. Handelsbanken Fonder AB grew its position in Halozyme Therapeutics by 76.9% during the 3rd quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock worth $112,715,000 after purchasing an additional 856,200 shares during the last quarter. Boston Trust Walden Corp increased its stake in Halozyme Therapeutics by 54.0% during the 3rd quarter. Boston Trust Walden Corp now owns 682,616 shares of the biopharmaceutical company’s stock valued at $39,073,000 after purchasing an additional 239,321 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Halozyme Therapeutics by 12.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock worth $99,363,000 after buying an additional 209,530 shares during the last quarter. Finally, South Street Advisors LLC purchased a new position in shares of Halozyme Therapeutics in the third quarter worth $9,812,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares of the company’s stock, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 2.40% of the stock is currently owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.